Physician profile
Michael Quist
NPI 1154858959
$3,110.06
in general payments reported to CMS, 2019-2025
13 companies · $671 in 2025
The $671 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $70.20 · 2021: $365 · 2022: $999 · 2023: $687 · 2024: $319 · 2025: $671.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,676.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,676.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $914.43 | 2022-2025 | Hydrus Microstent, Argos, Clareon |
| Sight Sciences, INC. | $581.88 | 2021-2025 | Sion Surgical Instrument, Omni Surgical System |
| Microsurgical Technology, INC. | $269.92 | 2023 | |
| Bausch & Lomb Americas INC. | $268.64 | 2022-2025 | Vyzulta, Xiidra, Miebo |
| Oyster Point Pharma, INC. | $222.61 | 2022 | |
| Glaukos Corporation | $220.99 | 2022-2023 | |
| Dompe US, INC. | $124.99 | 2021 | |
| Novartis Pharmaceuticals Corporation | $117.22 | 2022 | |
| Abbvie INC. | $116.05 | 2023 | |
| Rayner Intraocular Lenses Limited | $104.80 | 2022 | |
| Genentech USA, INC. | $70.20 | 2019 | |
| Allergan, INC. | $64.50 | 2021 | |
| New World Medical,INC. | $33.83 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Quist listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.